Drug updated on 10/24/2024
| Dosage Form | Injection (intravenous; 0.5mmol/mL) |
| Drug Class | Gadolinium-based contrast imaging agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in adult and pediatric patients aged 2 years and older for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Gadopiclenol provides similar diagnostic efficacy and accuracy as other gadolinium-based contrast agents (GBCAs), with comparable enhancement properties.
- Lower doses of gadopiclenol yield favorable diagnostic outcomes, with improved effectiveness observed at higher doses, suggesting dose efficiency compared to other GBCAs.
- No specific population types or subgroups were highlighted in the effectiveness findings.
- Gadopiclenol demonstrated a higher rate of liver retention compared to other gadolinium-based contrast agents (GBCAs), raising concerns for further investigation into long-term effects.
- Nonsignificant prolongation of the interval was observed in healthy individuals, suggesting the need for additional research on these effects.
- There is no population types or subgroups information available in the reviewed documents.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Elucirem (gadopiclenol) Prescribing Information. | 2024 | Guerbet LLC, Princeton, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Review of the Efficacy and Safety of Gadopiclenol: A Newly Emerging Gadolinium-Based Contrast Agent. | 2023 | Cureus |